The “JAK-pot” study compared the safety of JAK inhibitors (JAKis) to other biologic agents in the treatment of patients with rheumatoid arthritis (RA). touchIMMUNOLOGY were delighted to speak with Prof. Axel Finckh (University of Geneva, Geneva, Switzerland) to discuss real world safety and tolerability of JAKis and treatment discontinuation for JAKis compared to other treatments for RA in the JAK-pot study.
The abstract ‘Treatment discontinuation due to adverse events as an overall measure of tolerance and safety of JAK-inhibitors: An international collaboration of registries of rheumatoid arthritis patients (the “JAK-pot” study).‘ (Abstract number: OP0266) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
- What has been the impact of JAK inhibitors on the treatment paradigm for rheumatoid arthritis? (0:15)
- What is known about the tolerability and safety of JAK inhibitors in real world use? (1:20)
- How did treatment discontinuation for JAK inhibitors compare to those of other treatments, and what factors affected treatment discontinuation? (2:32)
- What were the conclusions of the investigators, and what further research is required? (4:02)
Disclosures: Axel Finckh discloses receiving grant/ research support from AbbVie, BMS, Galapagos, Eli-Lilly and Pfizer; and honoraria from Astra-Zeneca, AbbVie, BMS, Eli-Lilly and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!